Ergoteles’s Biodesix BDSX Stock Holding History

Ergoteles’s Portfolio BDSX Stock Details BDSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-733	Closed	-$33.7K	–	1270
2022 Q4	$33.7K	Buy	+733	New	+$19.9K	﹤0.01%	1325
2022 Q3	–	Sell	-1,111	Closed	-$36K	–	1553
2022 Q2	$36K	Buy	+1,111	New	+$36.1K	﹤0.01%	1569

Other funds holding BDSX

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

LCM

Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return

Ergoteles's BDSX Position: Q1 2023 in Review

Ergoteles sold out of Biodesix (BDSX) in Q1 2023, closing a stake of 733 shares — an estimated $33.7K sold.

Ergoteles first reported a position in BDSX in Q2 2022 and held it in 2 quarters. The position peaked at $36K in Q2 2022. 30 funds tracked by Wall St. Rank hold BDSX as of Q1 2023.

Ergoteles reported no remaining Biodesix position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 733 Biodesix shares in Q1 2023, an estimated $33.7K.
Ergoteles first reported a position in Biodesix in Q2 2022 and held it in 2 quarters.
Ergoteles's Biodesix position peaked at $36K in Q2 2022.
30 funds tracked by Wall St. Rank held Biodesix as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.